Prof Roger Nation

Group Leader
Monash Institute of Pharmaceutical Sciences
Monash University

Research Activities

The major research activities at FADDI are to target the burgeoning problem of emergence of multidrug-resistance among microbial pathogens by novel and rational therapeutic approaches.
  1. Pharmacokinetics, pharmacodynamics and toxicodynamics of colistin in animals, in cystic fibrosis patients and critically-ill patients: enhancing efficacy and reducing resistance and toxicities (NHMRC funded project, NIH grant application)
  2. Novel therapy and formulations against multidrug-resistant Gram-negative bacteria (NHMRC funded project, International Patent Application)
  3. Anti-pathogenic and anti-biofilm effects of antimicrobials (Partially funded by NHMRC)
  4. Novel combinations for bacterial infections
  5. Integration of pharmacokinetic, pharmacodynamic and toxicodynamic principles to assist in antimicrobial development and clinical use, to reduce resistance development and to optimise efficacy (e.g. linezolid - NHMRC funded project)
  6. Transport of drugs and metabolites across biological membranes
  7. Discovery of novel antibiotics against bacterial 'superbugs'


  1. Susceptibility testing including: minimum inhibitory and bactericidal concentrations; fractional inhibition concentrations (for combinations); population analysis profiles
  2. Time-kill experiments and post-antibiotic effect experiments (in vitro and in vivo)
  3. In vitro Pharmacokinetic/Pharmacodynamic (PK/PD) infection model
  4. In vitro biofilm model
  5. Animal infection models (e.g. mouse thigh and mouse lung)
  6. Discovery and purification of novel antimicrobial agents from natural products
  7. Quantitative analysis of drugs in biological fluids (using HPLC and bioassays)
  8. Determination of protein binding
  9. Organ perfusion (liver, kidney and placenta), PK in small (infected or uninfected) animals PK/PD analysis
  10. Pharmacokinetics of antimicrobials in small animals, including hepatic and renal handling of drugs and and metabolites
  11. Clinical trials
  12. Access to a wide range of equipment and expertise in the Faculty of Pharmacy


Professor John Turnidge and Associate Professor Kingsley Coulthard (Women's and Children's Hospital)
Associate Professor David Paterson (University of Pittsburg, USA)
Professor Alan Forrest (State University of New York at Buffalo, USA)
Associate Professor Denis Spelman (Alfred Hospital)
Professor Jeff Lipman (University of Queensland)
Professor Lyndsay Grayson and Dr Peter Ward (Austin Health)
Associate Professor Robert Milne (Sansom Institute, University of South Australia)
Dr Cynthia Whitchurch (Department of Microbiology, Monash University)
Dr Deborah Middleton (Australian Animal Health Laboratory, CSIRO)
Drs Ian Larson and Ben Boyd (Department of Pharmaceutics, Monash University)
Dr Alexandre Prehn Zavascki (Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul, Brazil)_
Dr John Mohr (University of Texas Medical School, USA)

Disease Models

Mouse thigh infection model
Mouse lung infection model

Other Lab Members

Dr David Kong
Ms Roxanne Owen
Mr Phillip Bergen
Ms Lauren Boak
Mr Robin Tan
Mr Rajesh Dudhani
Ms Stephanie Wallace
A/Prof Jian Li

Other members with similar research interests

prev next

Dr Rebecca Gorrell

Department of Biochemistry and Molecular Biology Monash University SEE FULL PROFILE >

Dr Kate Jeffrey

Gastrointestinal Unit, Department of Medicine Massachusetts General Hospital, Harvard Medical School SEE FULL PROFILE >

Prof Paul Hertzog

Centre for Innate Immunity and Infectious Diseases Hudson Institute of Medical Research SEE FULL PROFILE >

Upcoming Events

  • Aug 1

    VIIN Careers Evening 2024

    Walter and Eliza Hall Institute REGISTER | MORE INFO
  • Nov 8

    VIIN Young Investigator Symposium 2024

    Monash Institute of Pharmaceutical Sciences, Monash University MORE INFO
  • Feb 19

    Lorne Infection and Immunity Conference 2024

    Mantra Lorne MORE INFO